全膝关节置换术前维生素D补充的成本效益模型
该成本估算预测模型基于系统综述与Medicare报销数据,评估全膝关节置换术前补充25-羟基维生素D(25(OH)D)预防假体周围感染(PJI)的成本效益。每万例中,选择性筛查补充预计节省1,504,857美元,非选择性补充预计节省1,906,077美元,支持25(OH)D补充作为降低PJI风险的经济有效策略。
要点
- 每万例TKA中,非选择性25(OH)D补充预计节省1,906,077美元,高于选择性补充的1,504,857美元。
- 非选择性补充在翻修成本≥10,636美元、缺乏率≥1.1%、相对风险降低≥4.2%时具成本效益。
- 模型支持术前25(OH)D补充作为降低TKA后PJI风险的经济有效机制。
核心结论
- 该预测模型支持25(OH)D补充作为降低TKA后PJI风险的经济有效机制。
- 鉴于25(OH)D补充成本远低于血清实验室检测,非选择性补充比选择性补充更具成本效益。
研究设计与样本
- 成本估算预测模型,输入数据来自系统综述文献与Medicare报销公开数据。
- 评估初次TKA中选择性与非选择性25(OH)D补充预防PJI的成本效益。
主要发现
- 选择性术前25(OH)D筛查与补充每万例预计节省1,504,857美元(范围215,084-4,256,388美元)。
- 非选择性25(OH)D补充每万例预计节省1,906,077美元(范围616,304-4,657,608美元)。
- 单变量调整下,非选择性补充在PJI翻修成本≥10,636美元、缺乏率≥1.1%、相对风险降低≥4.2%时具成本效益。
关键数值与推荐
- 维生素D缺乏定义为血清25(OH)D < 20 ng/L。
- 非选择性补充成本效益条件:PJI翻修成本≥10,636美元、缺乏率≥1.1%、相对风险降低≥4.2%。
临床怎么用
- 可考虑对TKA患者术前非选择性补充25(OH)D以降低PJI风险并节省成本。
- 需进一步前瞻性研究评估这一可改变风险因素。
局限性
- 模型基于文献与报销数据预测,需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent studies have identified vitamin D deficiency (serum 25-hydroxyvitamin D [25(OH)D] < 20 ng/L) as a potentially modifiable risk factor for prosthetic joint infection (PJI) in arthroplasty. The purpose of this study is to determine whether implementation of preoperative 25(OH)D repletion is cost-effective for reducing PJI following total knee arthroplasty (TKA). METHODS: A cost estimation predictive model was generated to determine the utility of both selective and nonselective 25(OH)D repletion in primary TKA to prevent PJI. Input data on the incidence of 25(OH)D deficiency, relative complication rates, and costs of serum 25(OH)D repletion and 2-stage revision for PJI were derived from previously published literature identified using systematic review and publicly available data from Medicare reimbursement schedules. Mean, lower, and upper bounds of 1-year cost savings were computed for nonselective and selective repletion relative to no repletion. RESULTS: Selective preoperative 25(OH)D screening and repletion were projected to result in $1,504,857 (range, $215,084-$4,256,388) in cost savings per 10,000 cases. Nonselective 25(OH)D repletion was projected to result in $1,906,077 (range, $616,304-$4,657,608) in cost savings per 10,000 cases. With univariate adjustment, nonselective repletion is projected to be cost-effective in scenarios where revision for PJI costs ≥$10,636, incidence of deficiency is ≥1.1%, and when repletion has a relative risk reduction ≥4.2%. CONCLUSION: This predictive model supports the potential role of 25(OH)D repletion as a cost-effective mechanism of reducing PJI risk in TKA. Given the low cost of 25(OH)D repletion relative to serum laboratory testing, nonselective repletion appears to be more cost-effective than selective repletion. Further prospective investigation to assess this modifiable risk factor is warranted.
引用
- Arshi A, Shieh A, Adams JS, et al. Preoperative Vitamin D Repletion in Total Knee Arthroplasty: A Cost-Effectiveness Model. J Arthroplasty. 2019. PMID: 31983566. doi:10.1016/j.arth.2019.12.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。